Francisco Gonzalez
Medical · Winter Garden, FLNPI 1366638546
Payments from drug & device makers
Across 108 payments — averaging $20.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$327
- Novo Nordisk$295
- Acadia Pharmaceuticals Inc$250
- AstraZeneca$227
- Lilly USA, LLC$175
- Bayer$142
- plus $821 from 21 others
What the payments were for
- Food & beverage$2,236100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 15 | $327 |
| Novo Nordisk | 14 | $295 |
| Acadia Pharmaceuticals Inc | 2 | $250 |
| AstraZeneca | 15 | $227 |
| Lilly USA, LLC | 12 | $175 |
| Bayer | 6 | $142 |
| Clarus Therapeutics Inc. | 5 | $110 |
| Pfizer | 5 | $101 |
| Scilex Pharmaceuticals Inc. | 6 | $100 |
| Boehringer Ingelheim | 4 | $94 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $86 |
| Amgen | 2 | $43 |
| Paratek Pharmaceuticals, Inc. | 2 | $34 |
| GSK | 1 | $24 |
| Abbott | 1 | $23 |
| Amarin Pharma, Inc. | 1 | $23 |
| Xeris Pharmaceuticals, Inc. | 1 | $23 |
| Renalytix AI, Inc. | 1 | $23 |
| Idorsia Pharmaceuticals US Inc | 1 | $22 |
| Merck | 1 | $20 |
| Novartis | 1 | $18 |
| Amneal Pharmaceuticals LLC | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Biodelivery Sciences International, Inc. | 1 | $14 |
| Otsuka America Pharmaceutical, Inc. | 1 | $13 |
| Daiichi Sankyo Inc. | 1 | $13 |
| Sumitomo Pharma America, Inc. | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NUPLAZID$250
How this compares
$2,236 in reported general payments places this provider in the 70th percentile of 2,031 medical providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 11 | $10,051 |
| Amlodipine Besylate | 13 | $114 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $295 | $10,05111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,031 medical providers in Florida.
Other medical in Winter Garden
- Gary RubinRockledge$2.1M
- Shanna MirantiNaples$415K
- Krystie LennoxBoca Raton$245K
- Jihan RamadanWellington$238K
- Ilanit SamuelsMiami$211K
- Erin DouceyWinter Haven$202K
- Kathleen TrummerWellington$166K
- Sandra SnyderTampa$156K
- Francine PhillipsLand O Lakes$145K
- Chelsie FerrellDeland$132K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.